Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Sierra Oncology, Inc. (SRRA)
|
Add to portfolio |
|
|
|
| Price: |
$18.06
| | Metrics |
| OS: |
24.4
|
M
| |
-39
|
% ROE
|
| Market cap: |
$441
|
M
| |
-1553
|
% ROIC
|
|
Net cash:
|
$269
|
M
| |
$11.02
|
per share
|
|
EV:
|
$172
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($102)
|
M
| |
|
|
|
EBIT
|
($103)
|
M
| |
|
|
| EPS |
($7.02)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -100.0% | | | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | 100.0% | | | | | | |
| Research and development | 67.2 | 45.1 | 53.2 | 41.1 | 30.2 | 33.9 | 26.4 | 19.1 |
| General and administrative | 27.4 | 20.1 | 13.7 | 14.3 | 12.5 | 14.2 | 9.5 | 3.5 |
| EBIT | -94.6 | -64.9 | -67.0 | -55.4 | -42.6 | -48.1 | -35.8 | -22.6 |
| EBIT margin | | -21647.0% | | | | | | |
| Pre-tax income | -94.7 | -80.8 | -88.4 | -53.6 | -41.9 | -47.7 | -53.2 | -23.9 |
| Income taxes | 0.0 | 0.1 | -0.2 | -0.3 | 0.2 | 0.1 | 0.1 | 0.0 |
| Tax rate | 0.0% | | 0.2% | 0.6% | | | | |
| Net income | -94.7 | -80.9 | -88.3 | -53.3 | -42.0 | -47.9 | -453.2 | -73.7 |
| Net margin | | -26967.3% | | | | | | |
| |
| Diluted EPS | ($7.14) | ($7.70) | ($30.30) | ($30.16) | ($33.68) | ($1.58) | ($31.47) | ($69.08) |
| Shares outstanding (diluted) | 13.3 | 10.5 | 2.9 | 1.8 | 1.2 | 30.2 | 14.4 | 1.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|